Sarepta Therapeutics (NASDAQ:SRPT) Receives “Neutral” Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential downside of 0.12% from the company’s previous close.

Several other equities analysts have also weighed in on SRPT. Scotiabank cut their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Morgan Stanley cut their price objective on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada reduced their target price on Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating for the company in a research note on Wednesday, May 7th. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Finally, UBS Group cut their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $122.61.

Sarepta Therapeutics Trading Up 0.2%

Shares of NASDAQ:SRPT opened at $40.05 on Thursday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12-month low of $34.10 and a 12-month high of $173.25. The business has a 50 day moving average of $56.56 and a two-hundred day moving average of $95.81. The company has a market capitalization of $3.94 billion, a PE ratio of 32.04 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. During the same period last year, the firm earned $0.73 earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 80.2% compared to the same quarter last year. As a group, analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently modified their holdings of the company. Manchester Capital Management LLC raised its stake in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at approximately $36,000. Steward Partners Investment Advisory LLC lifted its holdings in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 194 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its position in Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 216 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.